4-aminopyridine and Conjugate Nystagmus studies

Research Excerpts

Excerpt	Relevance	Reference
"The therapeutic effects of 4-aminopyridine (4AP) were investigated in a randomized, double-blind, crossover trial in 10 subjects with familial episodic ataxia with nystagmus."	9.15	A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. ( Adrion, C; Brandt, T; Claassen, J; Dichgans, M; Freilinger, T; Jahn, K; Jen, JC; Jurkat-Rott, K; Kalla, R; Klopstock, T; Lehmann-Horn, F; Mansmann, U; Neugebauer, H; Spiegel, R; Strupp, M, 2011)
"Patients with episodic ataxia type 2 (EA2) can often be successfully treated with acetazolamide."	9.11	Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. ( Brandt, T; Dichgans, M; Freilinger, T; Glasauer, S; Kalla, R; Strupp, M, 2004)
"Episodic ataxia type 2 is an autosomal dominant channelopathy, caused by genetic variants in the voltage-dependent calcium channel a-1 subunit (CACNA1A), which is characterized by intermittent episodes of vertigo and ataxia."	5.72	The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. ( Brieva-Ruiz, L; González-Mingot, C; López-Ortega, R, 2022)
"The therapeutic effects of 4-aminopyridine (4AP) were investigated in a randomized, double-blind, crossover trial in 10 subjects with familial episodic ataxia with nystagmus."	5.15	A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. ( Adrion, C; Brandt, T; Claassen, J; Dichgans, M; Freilinger, T; Jahn, K; Jen, JC; Jurkat-Rott, K; Kalla, R; Klopstock, T; Lehmann-Horn, F; Mansmann, U; Neugebauer, H; Spiegel, R; Strupp, M, 2011)
"Patients with episodic ataxia type 2 (EA2) can often be successfully treated with acetazolamide."	5.11	Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. ( Brandt, T; Dichgans, M; Freilinger, T; Glasauer, S; Kalla, R; Strupp, M, 2004)
" The efficacy of acetyl-DL-leucine as a potential new symptomatic treatment for cerebellar diseases has been demonstrated in three case series."	4.93	Update on the pharmacotherapy of cerebellar and central vestibular disorders. ( Feil, K; Kalla, R; Muth, C; Strupp, M; Teufel, J, 2016)
"Previous theories assumed that the beneficial effect of the potassium channel blocker 4-aminopyridine (4-AP) for patients suffering from downbeat nystagmus (DBN) or episodic ataxia type 2 (EA2) is due to an increase of excitability of cerebellar Purkinje cells (PC)."	3.77	The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus. ( Glasauer, S; Rössert, C; Strupp, M, 2011)
"Acquired brain injury can cause eye movement disorders which may include: strabismus, gaze deficits and nystagmus, causing visual symptoms of double, blurred or 'juddery' vision and reading difficulties."	2.58	Interventions for eye movement disorders due to acquired brain injury. ( Dodridge, CS; Evans, JR; Garcia-Finana, M; Hanna, K; Howard, C; Jarvis, KA; Maan, T; MacDiarmid, SL; Noonan, CP; North, L; Rodgers, H; Rowe, FJ, 2018)
"Pharmacological treatment of cerebellar ataxias and cerebellar nystagmus still remains difficult."	2.53	Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus. ( Bremova, T; Feil, K; Muth, C; Schniepp, R; Strupp, M; Teufel, J, 2016)
"Episodic ataxia type 2 is an autosomal dominant channelopathy, caused by genetic variants in the voltage-dependent calcium channel a-1 subunit (CACNA1A), which is characterized by intermittent episodes of vertigo and ataxia."	1.72	The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. ( Brieva-Ruiz, L; González-Mingot, C; López-Ortega, R, 2022)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	14 (41.18)	29.6817
2010's	19 (55.88)	24.3611
2020's	1 (2.94)	2.80

Authors	Studies
González-Mingot, C	1
López-Ortega, R	1
Brieva-Ruiz, L	1
Rowe, FJ	1
Hanna, K	1
Evans, JR	1
Noonan, CP	1
Garcia-Finana, M	1
Dodridge, CS	1
Howard, C	1
Jarvis, KA	1
MacDiarmid, SL	1
Maan, T	1
North, L	1
Rodgers, H	1
Claassen, J	5
Feil, K	4
Bardins, S	5
Teufel, J	6
Spiegel, R	7
Kalla, R	13
Schneider, E	4
Jahn, K	8
Schniepp, R	2
Strupp, M	18
Claaßen, J	1
Habs, M	1
Faldon, M	1
Kennard, C	1
Danchaivijitr, C	1
Rettinger, N	4
Brandt, T	11
Bronstein, A	1
Shaikh, AG	2
Marti, S	2
Tarnutzer, AA	1
Palla, A	1
Crawford, TO	1
Zee, DS	1
Straumann, D	3
Beck, R	1
Günther, L	1
Xiong, G	1
Potschka, H	1
Böning, G	1
Bartenstein, P	2
Dieterich, M	2
la Fougère, C	2
Zwergal, A	2
Bremova, T	1
Muth, C	2
Wagner, J	1
Glasauer, S	7
Rössert, C	2
Sander, T	4
Sprenger, A	4
Naumann, T	1
Helmchen, C	4
Pieh-Beisse, C	1
Lagrèze, WA	1
Adrion, C	1
Mansmann, U	1
Klopstock, T	1
Freilinger, T	2
Neugebauer, H	1
Dichgans, M	2
Lehmann-Horn, F	1
Jurkat-Rott, K	1
Jen, JC	1
Hahn, A	2
Hess, E	1
Classen, J	1
Anciães da Silva, F	1
Farahmand, P	1
Ehrhardt, D	1
Eggenberger, E	1
Kremmyda, O	1
Velez, L	1
Shirazi, F	1
Goto, C	1
Shepherd, G	1
Roth, BA	1
Leigh, RJ	2
Schüler, O	1
Krafczyk, S	1
Schautzer, F	2
Büttner, U	4
Lehnen, N	1
Halmagyi, GM	1
Rambold, H	3
Kömpf, D	1
Zils, E	1
Bense, S	1
Best, C	1
Buchholz, HG	1
Wiener, V	1
Schreckenberger, M	1
Gottschalk, S	1
Trillenberg, P	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Examining the Effect of Eye Gaze Technology on Children With Cortical Visual Impairment and Its Impact on Occupational Performance[NCT06067607]		10 participants (Anticipated)	Interventional	2023-02-01	Recruiting
Phase 2 Study of 4-Aminopyridine for the Treatment of Episodic Ataxia Type 2[NCT01543750]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Article	Year
Interventions for eye movement disorders due to acquired brain injury. The Cochrane database of systematic reviews, 2018, 03-05, Volume: 3 Topics: 4-Aminopyridine; Abducens Nerve Diseases; Amifampridine; Amines; Baclofen; Botulinum Toxins; Brain I	2018
Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus. Cerebellum (London, England), 2016, Volume: 15, Issue:1 Topics: 4-Aminopyridine; Cerebellar Ataxia; Chlorzoxazone; Drug Therapy; Humans; Leucine; Muscle Relaxants,	2016
Update on the pharmacotherapy of cerebellar and central vestibular disorders. Journal of neurology, 2016, Volume: 263 Suppl 1 Topics: 4-Aminopyridine; Cerebellar Diseases; Humans; Leucine; Male; Nystagmus, Pathologic; Potassium Channe	2016
[Pharmacotherapy of central oculomotor disorders]. Der Nervenarzt, 2008, Volume: 79, Issue:12 Topics: 4-Aminopyridine; Amifampridine; Amines; Baclofen; Cyclohexanecarboxylic Acids; Diagnosis, Differenti	2008
Medical treatment of acquired nystagmus. Current opinion in ophthalmology, 2012, Volume: 23, Issue:6 Topics: 4-Aminopyridine; Baclofen; GABA-B Receptor Agonists; Humans; Nystagmus, Pathologic; Potassium Channe	2012

Article	Year
A randomised double-blind, cross-over trial of 4-aminopyridine for downbeat nystagmus--effects on slowphase eye velocity, postural stability, locomotion and symptoms. Journal of neurology, neurosurgery, and psychiatry, 2013, Volume: 84, Issue:12 Topics: 4-Aminopyridine; Adult; Age Factors; Aged; Cross-Over Studies; Double-Blind Method; Eye Movements; F	2013
A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology, 2011, Jul-19, Volume: 77, Issue:3 Topics: 4-Aminopyridine; Activities of Daily Living; Adolescent; Adult; Aged; Aged, 80 and over; Ataxia; Cal	2011
Comparison of 10-mg doses of 4-aminopyridine and 3,4-diaminopyridine for the treatment of downbeat nystagmus. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2011, Volume: 31, Issue:4 Topics: 4-Aminopyridine; Aged; Amifampridine; Capsules; Cross-Over Studies; Double-Blind Method; Eye Movemen	2011
Treatment of downbeat nystagmus with 3,4-diaminopyridine: a placebo-controlled study. Neurology, 2003, Jul-22, Volume: 61, Issue:2 Topics: 4-Aminopyridine; Action Potentials; Aged; Aged, 80 and over; Amifampridine; Cerebellum; Cross-Over S	2003
Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology, 2004, May-11, Volume: 62, Issue:9 Topics: 4-Aminopyridine; Acetazolamide; Adolescent; Adult; Ataxia; Calcium Channels; Humans; Male; Middle Ag	2004
4-aminopyridine restores vertical and horizontal neural integrator function in downbeat nystagmus. Brain : a journal of neurology, 2007, Volume: 130, Issue:Pt 9 Topics: 4-Aminopyridine; Adult; Aged; Atrophy; Cerebellum; Eye Movements; Female; Fixation, Ocular; Humans;	2007

4-aminopyridine and Conjugate Nystagmus

Research Excerpts

Research

Studies (34)

Authors

Clinical Trials (2)

Trial Overview

Reviews

Trials

Other Studies

Article	Year
The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2022, Volume: 43, Issue:8 Topics: 4-Aminopyridine; Acetazolamide; Adult; Ataxia; Cerebellar Ataxia; Female; Humans; Male; Middle Aged;	2022
Dalfampridine in patients with downbeat nystagmus--an observational study. Journal of neurology, 2013, Volume: 260, Issue:8 Topics: 4-Aminopyridine; Aged; Aged, 80 and over; Brain; Delayed-Action Preparations; Eye Movements; Female;	2013
Transition from downbeat to upbeat nystagmus caused by 4-aminopyridine. Journal of neurology, 2013, Volume: 260, Issue:5 Topics: 4-Aminopyridine; Aged; Eye Movements; Female; Humans; Longitudinal Studies; Nystagmus, Pathologic; P	2013
Does 4-aminopyridine "beat" downbeat nystagmus? Journal of neurology, neurosurgery, and psychiatry, 2013, Volume: 84, Issue:12 Topics: 4-Aminopyridine; Eye Movements; Female; Humans; Locomotion; Male; Nystagmus, Pathologic; Postural Ba	2013
Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia. Journal of neurology, 2013, Volume: 260, Issue:11 Topics: 4-Aminopyridine; Adult; Ataxia Telangiectasia; Humans; Middle Aged; Nystagmus, Pathologic; Potassium	2013
The mixed blessing of treating symptoms in acute vestibular failure--evidence from a 4-aminopyridine experiment. Experimental neurology, 2014, Volume: 261 Topics: 4-Aminopyridine; Animals; Brain; Disease Models, Animal; Drug Administration Schedule; Fluorodeoxygl	2014
Modelling drug modulation of nystagmus. Progress in brain research, 2008, Volume: 171 Topics: 4-Aminopyridine; Animals; Eye Movements; Feedback; Guinea Pigs; Humans; Neurons; Nystagmus, Patholog	2008
Effect of 4-aminopyridine on gravity dependence and neural integrator function in patients with idiopathic downbeat nystagmus. Journal of neurology, 2011, Volume: 258, Issue:4 Topics: 4-Aminopyridine; Adult; Aged; Aged, 80 and over; Analysis of Variance; Eye Movements; Female; Gravit	2011
[Pharmacological treatment of nystagmus]. Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2011, Volume: 108, Issue:2 Topics: 4-Aminopyridine; Amines; Anticonvulsants; Baclofen; Cyclohexanecarboxylic Acids; Dopamine Agents; Ga	2011
The role of regularity and synchrony of cerebellar Purkinje cells for pathological nystagmus. Annals of the New York Academy of Sciences, 2011, Volume: 1233 Topics: 4-Aminopyridine; Animals; Ataxia; Computer Simulation; Disease Models, Animal; Electrophysiological	2011
A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology, 2011, Nov-29, Volume: 77, Issue:22 Topics: 4-Aminopyridine; Ataxia; Female; Humans; Intracellular Signaling Peptides and Proteins; Male; Nystag	2011
Aminopyridine treatment in a patient with bilateral vestibular failure and cryptogenic downbeat nystagmus. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2012, Volume: 32, Issue:2 Topics: 4-Aminopyridine; Female; Humans; Male; Nystagmus, Pathologic; Potassium Channel Blockers	2012
4-Aminopyridine suppresses positional nystagmus caused by cerebellar vermis lesion. Journal of neurology, 2013, Volume: 260, Issue:1 Topics: 4-Aminopyridine; Cerebellar Diseases; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Magnet	2013
Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study. Journal of neurology, 2013, Volume: 260, Issue:2 Topics: 4-Aminopyridine; Adult; Ataxia; Calcium Channels; Humans; Male; Middle Aged; Nystagmus, Pathologic;	2013
Opisthotonic posturing with neuromuscular irritability attributable to 4-aminopyridine ingestion by a healthy pediatric patient. Pediatrics, 2003, Volume: 111, Issue:1 Topics: 4-Aminopyridine; Humans; Infant; Male; Nystagmus, Pathologic; Spasm; Tachycardia	2003
Potassium channels, the cerebellum, and treatment for downbeat nystagmus. Neurology, 2003, Jul-22, Volume: 61, Issue:2 Topics: 4-Aminopyridine; Amifampridine; Humans; Models, Neurological; Nystagmus, Pathologic; Potassium Chann	2003
4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology, 2004, Apr-13, Volume: 62, Issue:7 Topics: 4-Aminopyridine; Aged; Humans; Male; Nystagmus, Pathologic; Postural Balance; Potassium Channel Bloc	2004
Upbeat about downbeat nystagmus. Neurology, 2004, Aug-24, Volume: 63, Issue:4 Topics: 4-Aminopyridine; Amifampridine; Animals; Calcium Channels; Calcium Channels, N-Type; Calcium Channel	2004
Effect of 3,4-diaminopyridine on the gravity dependence of ocular drift in downbeat nystagmus. Neurology, 2004, Aug-24, Volume: 63, Issue:4 Topics: 4-Aminopyridine; Amifampridine; Cerebellum; Diplopia; Electronystagmography; Female; Gravitation; He	2004
4-aminopyridine restores visual ocular motor function in upbeat nystagmus. Journal of neurology, neurosurgery, and psychiatry, 2005, Volume: 76, Issue:3 Topics: 4-Aminopyridine; Adult; Dose-Response Relationship, Drug; Humans; Male; Nystagmus, Pathologic; Potas	2005
Effect of 3,4-diaminopyridine on the postural control in patients with downbeat nystagmus. Annals of the New York Academy of Sciences, 2005, Volume: 1039 Topics: 4-Aminopyridine; Aged, 80 and over; Amifampridine; Cerebellum; Eye Movements; Female; Fixation, Ocul	2005
18F-fluorodeoxyglucose hypometabolism in cerebellar tonsil and flocculus in downbeat nystagmus. Neuroreport, 2006, Apr-24, Volume: 17, Issue:6 Topics: 4-Aminopyridine; Aged; Cerebellum; Eye Movements; Female; Fluorodeoxyglucose F18; Humans; Imaging, T	2006
Beneficial effects of 3,4-diaminopyridine on positioning downbeat nystagmus in a circumscribed uvulo-nodular lesion. Journal of neurology, 2007, Volume: 254, Issue:8 Topics: 4-Aminopyridine; Adult; Amifampridine; Cerebellar Diseases; Humans; Magnetic Resonance Imaging; Male	2007